Compare FG & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FG | LIVN |
|---|---|---|
| Founded | 1959 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | 3300 |
| Industry | Life Insurance | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.3B |
| IPO Year | 2023 | 2015 |
| Metric | FG | LIVN |
|---|---|---|
| Price | $23.19 | $77.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $31.00 | ★ $72.43 |
| AVG Volume (30 Days) | 470.7K | ★ 521.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.24 | ★ 2.33 |
| Revenue | ★ $5,731,000,000.00 | N/A |
| Revenue This Year | $7.94 | $9.79 |
| Revenue Next Year | $5.51 | $6.63 |
| P/E Ratio | ★ $18.66 | $33.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.57 | $48.82 |
| 52 Week High | $35.33 | $85.76 |
| Indicator | FG | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 41.42 |
| Support Level | $22.18 | $74.99 |
| Resistance Level | $25.36 | $82.39 |
| Average True Range (ATR) | 0.70 | 2.08 |
| MACD | 0.12 | -0.32 |
| Stochastic Oscillator | 21.80 | 4.45 |
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.